![]() | ![]() |
Formats: |
||||||||||||||||||||||||||||||||||
Copyright © 2009 Das et al.; licensee BioMed Central Ltd. Cyclin D1 fine-tunes the neurogenic output of embryonic retinal progenitor cells 1Department of Ophthalmology and Visual Sciences, John A Moran Eye Center, University of Utah, Salt Lake City, UT 84132, USA 2Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, UT 84132, USA 3Department of Pathology, Harvard Medical School, Boston, MA 02115, USA 4Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA Corresponding author.Gaurav Das: gaurav.das/at/hsc.utah.edu; Yoon Choi: yoon_choi/at/dfci.harvard.edu; Piotr Sicinski: peter_sicinski/at/dfci.harvard.edu; Edward M Levine: ed.levine/at/utah.edu Received September 25, 2008; Accepted May 5, 2009. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background Maintaining the correct balance of proliferation versus differentiation in retinal progenitor cells (RPCs) is essential for proper development of the retina. The cell cycle regulator cyclin D1 is expressed in RPCs, and mice with a targeted null allele at the cyclin D1 locus (Ccnd1-/-) have microphthalmia and hypocellular retinas, the latter phenotype attributed to reduced RPC proliferation and increased photoreceptor cell death during the postnatal period. How cyclin D1 influences RPC behavior, especially during the embryonic period, is unclear. Results In this study, we show that embryonic RPCs lacking cyclin D1 progress through the cell cycle at a slower rate and exit the cell cycle at a faster rate. Consistent with enhanced cell cycle exit, the relative proportions of cell types born in the embryonic period, such as retinal ganglion cells and photoreceptor cells, are increased. Unexpectedly, cyclin D1 deficiency decreases the proportions of other early born retinal neurons, namely horizontal cells and specific amacrine cell types. We also found that the laminar positioning of horizontal cells and other cell types is altered in the absence of cyclin D1. Genetically replacing cyclin D1 with cyclin D2 is not efficient at correcting the phenotypes due to the cyclin D1 deficiency, which suggests the D-cyclins are not fully redundant. Replacement with cyclin E or inactivation of cyclin-dependent kinase inhibitor p27Kip1 restores the balance of RPCs and retinal cell types to more normal distributions, which suggests that regulation of the retinoblastoma pathway is an important function for cyclin D1 during embryonic retinal development. Conclusion Our findings show that cyclin D1 has important roles in RPC cell cycle regulation and retinal histogenesis. The reduction in the RPC population due to a longer cell cycle time and to an enhanced rate of cell cycle exit are likely to be the primary factors driving retinal hypocellularity and altered output of precursor populations in the embryonic Ccnd1-/- retina. Background The vertebrate retina is composed of seven major cell classes that arise from a common source, the retinal progenitor cell (RPC) population. Although RPCs at any given stage are largely multipotential, they are constrained such that each cell class is generated in a temporal, albeit overlapping order. Production of retinal ganglion cells (RGCs), horizontal cells, and cone photoreceptors is initiated at the earliest stage of retinal neurogenesis, followed by amacrine cells and rod photoreceptors, which is then followed by bipolar cells and Müller glia. The relative proportion of cells in each class differs widely. For example, cones account for approximately 3% and rods approximately 97% of the photoreceptors in the mouse retina, and rod photoreceptors are the most abundant cell class accounting for approximately 70% of all retinal cells [1]. In general, the early-born cell classes constitute a much smaller percentage of the retina than do the late-born cell classes [1,3]. While cell death contributes to the final cell distribution of the adult retina [4,6], the initial allocation of precursor cells (that is, RPCs that exit the cell cycle) to each class is a predominant factor in setting their relative proportions. In addition to generating the different cell classes, RPCs need to proliferate in order to produce enough cells to populate the retina. In the rat retina, RPC proliferation drives an approximately 400-fold expansion of total cell number in a 17-day period between embryonic day (E)14 and postnatal day (P)8 [7]. This interval also corresponds to when the bulk of the RPC population exits the cell cycle to generate precursors [2]. Thus, RPCs are exposed to competing forces that either influence them to stay in the cell cycle in order to produce enough cells or to exit the cell cycle at the appropriate time in order to generate the correct proportion of cells corresponding to each cell class. It is generally accepted that multiple cell-extrinsic and -intrinsic factors play important roles in establishing the correct balance between RPC proliferation and precursor generation during development [8-10]. While it is important to understand how these different factors are integrated into networks, an understanding of the molecular mechanisms used to exit the cell cycle during the transition from RPC to precursor is also needed. D-type cyclins promote progression from G1 to S phase in dividing cells by activating cyclin-dependent kinases 4 or 6 (CDK4/6) and by sequestering cyclin-dependent kinase inhibitors such as cyclin-dependent kinase inhibitor 1B (CDKN1B, henceforth referred to as P27KIP1) [11]. The net result is enhanced CDK2 activity, inactivation of retinoblastoma proteins, and activation of DNA replication. D-cyclins are also downstream of various signaling pathways and, thus, are well positioned to co-ordinate cell cycle progression with the extracellular environment [11,12]. Mice have three D-cyclin genes: cyclin D1 (Ccnd1), cyclin D2 (Ccnd2) and cyclin D3 (Ccnd3). The expression and requirement of the D-cyclins during development is tissue specific [13]. Surprisingly, mouse embryos lacking all three D-cyclins develop until E16.5, when they die due to heart abnormalities combined with severe anemia [14]. Although developmental defects are apparent in these mice prior to E16.5, proliferation of many tissues, including the retina, still occurs, indicating that the D-cyclins are not absolutely required for cell cycle progression. Ccnd1 is the predominant D-cyclin in the developing retina and is highly expressed in RPCs but absent from exited precursors and differentiated cells [15,18] (this study). Zebrafish embryos treated with a Ccnd1 morpholino exhibit small eye [19] and mice lacking Ccnd1 have small eyes and hypocellular retinas due to reduced RPC proliferation and postnatal retinal cell death [17,20,21]. However, the impact of Ccnd1 on embryonic retinal development has not been directly assessed. In this study, we characterized the embryonic retinal phenotype in Ccnd1-/- mice. We found that the cell cycle rate of the Ccnd1-/- RPC population is slower than normal and this population undergoes a faster rate of depletion due to an increased rate of cell cycle exit. Consistent with this, RGCs and photoreceptors are overrepresented. Surprisingly, other early-born embryonic cell classes in the retina, namely horizontal and amacrine cells, are underrepresented in the absence of Ccnd1. Analysis of retinas from newborn mice in which Ccnd1 is replaced by Ccnd2 reveal that the proportions of at least some cell types remain altered, suggesting a unique requirement for Ccnd1 in RPCs. We also analyzed the retinas of newborn mice in which Ccnd1 is replaced by human Cyclin E (hCcne) or in Ccnd1-/-, p27Kip1-/- double mutants and found that the proportions of cell types approach a more normal distribution. These findings led us to propose that Ccnd1 controls the timing of cell cycle exit in embryonic RPCs and, by doing so, contributes to the appropriate allocation of precursor cells to each cell class. We also propose that Ccnd1 contributes to the correct proliferative expansion of the retina by influencing the time it takes for RPCs to transit through the cell cycle and by maintaining a sufficient number of RPCs during the period of neurogenesis. Materials and methods Animals Ccnd1-/- mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Drs Matthew Fero and James Roberts (Fred Hutchinson Cancer Center, Seattle, WA) kindly provided the p27Kip1-/- mice. The mouse strains containing the Ccnd2 cDNA targeted to the Ccnd1 locus (Ccnd1D2/D2) and human Ccne cDNA targeted to the Ccnd1 locus (Ccnd1hE/hE) were maintained in the Sicinski laboratory. The noon of the day a vaginal plug was observed was designated E0.5. Genotyping was done as previously described [17,22-24]. All animal use and care was conducted in accordance with protocols approved by the University of Utah Institutional Animal Care and Use Committee and set forth in the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals. Efforts were made to minimize discomfort to animals and, when possible, the number of animals needed per analysis was kept to a minimum. Immunohistochemistry Tissue preparation and immunohistochemistry were done as previously described [25]. Radial cryosections through the retina were cut at a thickness of 10 μm. Primary antibodies are listed in Table 1. Antigen unmasking (0.18 mM citric acid, 77 μM sodium citrate, pH 6.0, 15 minutes, 90–95°C) was performed prior to incubation with the proliferating cell nuclear antigen (PCNA) antibody. Hydrochloric acid treatment (2N HCl, 30 minutes, room temperature) was performed prior to incubation with the bromodeoxyuridine (BrdU) antibody.
Image analysis Sections were analyzed by epi-fluorescence using a Nikon E-600 microscope and images captured in gray scale mode with a Spot-RT slider CCD camera (Diagnostic Instruments, Sterling Heights, MI, USA). Confocal images were scanned using an Olympus Fluoview 1000 microscope. Color (RGB) images were assembled from individual monochrome channels using Photoshop CS (Adobe Systems Inc., San Jose, CA, USA). The levels function was used to adjust the digital images to be consistent with visual observations. Marker quantification and statistical analysis The relative proportions, lineal densities, or areal densities of marker-positive (+) or -negative (-) cells were quantified at E12, E14.5 and P0. For each genotype, a minimum of three animals from at least two litters was sampled. For each animal, three different non-adjacent central-retina sections were used for cell counting. At E12, epi-fluorescence images of whole retinal sections were captured. Cell populations were quantified over the total area of the sections (marker+ cells/mm2 retina). The exception was for PCNA+ cells, which were quantified as a percentage of the total cell population ((PCNA+ cells/DAPI+ cells) × 100). PCNA+ population was sampled from the dorsal retina, where neurogenesis initiates. At E14.5, marker+ cells were calculated as a percentage of total cells (marker+ cells/DAPI+ cells) from 400×-magnified confocal images (1,600 × 1,600 resolution), captured at comparable dorsal-medial regions. At P0, marker+ cells were quantified as a percentage of total cells from confocal images of medial-central retina, within 200 μm of the optic nerve head. Neurofilament medium (NEFM)+ horizontal and SRY-box containing gene 2 (SOX2)+ amacrine cells were quantified as a ratio of the unit length of apical surface of the retina (marker+ cells/mm retina) because of their sparse, linear distribution. The entire peripheral-central-peripheral extent of individual sections was used for these measurements. All cell counts, area, and length measurements were done using Adobe Photoshop CS and ImageJ (NIH). Students' t-test was performed using Kaleidagraph statistical and graphing software (Synergy Software, Reading, PA, USA) to determine statistical significance in the marker+ cell population between mutant and control samples. In all graphs, numbers inside bars indicate the number of samples analyzed. Error bars indicate standard deviation. Window-labeling using thymidine analogs to measure cell cycle times Retinas with lens attached were cultured for 2.5 hours and sequentially exposed to two thymidine analogs for defined intervals. At P0, 5-iodo-2'-deoxy-uridine (IdU) was added to the culture medium for the first 2 hours and replaced with 5-bromo-2'-deoxy-uridine (BrdU) for the final 30 minutes. At E14.5, BrdU was added to the culture medium for the first 2 hours and replaced with 5-ethynyl-2'-deoxy-uridine (EdU) for the final 30 minutes. As previously described [26-28], a combination of mouse anti-BrdU (clone B44; BD Biosciences, San Jose, CA, USA) and rat anti-BrdU (clone BU1/75; Serotec, Raleigh, NC, USA) were used to detect the analogs at P0. For the E14.5 samples, the mouse anti-BrdU antibody was used to detect BrdU (EdU is also detected), and EdU was specifically detected using the Click-it Reaction (Molecular Probes, Carlsbad, CA, USA) [29]. PCNA was used at both ages to identify RPCs in all phases of the cell cycle [15]. The length of the cell cycle (Tc) in hours was calculated by the formulae:
or
and the length of the S-phase (Ts) in hours was calculated by the formulae:
or
At E14.5 cell counts were done from a single central field on each section (at least three sections per animal), generally on the same side. At P0, cell counts were done on six fields spanning an entire section (at least of two sections per animal). Dorsal-ventral orientation was lost upon dissecting eyes out. A more detailed analysis of this assay will appear in a forthcoming manuscript (GD and EML). Cell cycle exit assay and RGC birthdating Pregnant mice were injected once with a dose of BrdU (10 mg/ml stock in 0.1 M Tris (pH 7): 100 μg/gm of body weight injected) at E13.5 or E18.5 and sacrificed 24 hours later at E14.5 and P0.5, respectively. Sections were co-labeled with antibodies against BrdU and PCNA and imaged by confocal microscopy. The cell cycle exit index was calculated as the percentage of BrdU+ cells that were PCNA- ((BrdU+, PCNA- cells/Total BrdU+ cells) × 100). To measure the production of RGCs from RPCs, sections from the same animals used for the cell cycle exit index were co-labeled with antibodies against BrdU and POU domain, class 4, transcription factor 2 (POU4F2; formerly BRN3B). The index for RGC production was calculated as the percentage of BrdU+ cells that were POU4F2+ ((BrdU+, POU4F2+ cells/Total BrdU+ cells) × 100). Cell counts were done from a single dorsal-central field per section (at least two sections per animal) retina at E14.5. For P0 samples, counts were done from two peripheral fields at opposite ends per section (at least two sections per animal). Results CCND1 expression pattern during the early stages of retinal development In the mouse retina, CCND1 protein is expressed as early as E11 [17]. However, a systematic analysis of its expression pattern during early retinal development has not been done. Therefore, we examined CCND1 expression from E9.5 to E14.5, the period of optic cup formation and onset of retinal neurogenesis (Figure (Figure1).1
Patterning and apoptosis are unaltered by Ccnd1 inactivation at embryonic ages Since Ccnd1 is expressed during optic cup formation, the hypocellularity of the Ccnd1-/- retina could be due to altered regional patterning. However, analysis of several markers of optic vesicle and cup patterning did not reveal differences in the establishment or size of the neural retinal domain (Additional file 1). Likewise, we did not observe obvious differences in apoptosis at any of the embryonic ages analyzed as revealed by activated caspase 3 (CASP3) immunoreactivity (Additional file 2) or by TUNEL assay (data not shown). Cell cycle time is longer in the Ccnd1-/- RPC population Having ruled out major changes in retinal domain formation and cell death, we measured other parameters that could cause the hypocellularity observed in the Ccnd1-/- retina. At birth, Ccnd1-/- retinas show a three-fold decrease in total cells and a concomitant three-fold decrease in cells that incorporate tritiated thymidine [21]. While these findings suggest reduced RPC proliferation prior to P0, we directly analyzed proliferative activity during the embryonic period, first by detection of phosphorylated histone H3 (pHH3), a marker of RPCs in M-phase (Additional file 3) [15]. Fewer pHH3+ cells are evident by E14.5, confirming that RPC proliferation is reduced in the embryonic Ccnd1-/- retina. To get an estimate of the cell cycle time and related measures, we adapted a window-labeling paradigm that utilizes two thymidine analogs that can be differentially detected [27] (manuscript in preparation). Frozen sections from P0 retinas were triple-labeled with a mouse anti-BrdU antibody identifying both IdU and BrdU (Figure 2A, D
We observed that the cell cycle time (Tc) of the Ccnd1-/- RPC population was increased relative to that of the wild-type RPC population at E14.5 and P0 (Figure (Figure2G).2G Increased cell cycle exit in the Ccnd1-/- retina reduces the relative size of the RPC population In addition to a slower cell cycle rate, a reduction in size of the RPC population due to enhanced cell cycle exit could also contribute to the proliferation problems associated with the hypocellularity of the Ccnd1-/- retina. To assess this, we first examined the expression pattern of PCNA and measured the proportion of PCNA+ cells relative to the total cell population at E12, E14.5 and P0 (Figure 3A–G
These observations suggest that RPCs in the Ccnd1-/- retina are exiting the cell cycle at a comparably more rapid rate than normal. To assess this more directly, a cell cycle exit index was measured for the interval between E13.5 to E14.5, when RPC proliferation is robust and neurogenesis is well underway, and later between E18.5 and P0.5 (Figure 3H–O Enhanced cell cycle exit in the Ccnd1-/- retina leads to increased proportions of RGCs and photoreceptors, but not an earlier onset of neurogenesis Enhanced cell cycle exit can lead to two non-mutually exclusive changes in neurogenesis: an earlier onset or enhanced neuron production from prematurely exiting RPCs after onset. Importantly, either change could increase the proportions of early born neuronal populations such as RGCs. To determine if neurogenesis initiates earlier than normal in the Ccnd1-/- retina, we examined the expression of acTUBB3 and the transcription factor POU4F2, a marker of RGC precursors [32,33]. Cells positive for either marker were not observed at E11 or earlier regardless of genotype (data not shown; Figure 4A, E
To determine whether Ccnd1 inactivation increases the proportion of early-born neurons, we examined the expression pattern of POU4F2 after the onset of neurogenesis (Figure 4B–D, F–H To confirm that the greater proportion of RGCs is correlated with enhanced RPC cell cycle exit, we directly measured the proportion of RPCs that were becoming POU4F2+ RGCs in a given time period. Using the same samples as for the cell cycle exit assay described above, we calculated the percentage of BrdU+ cells that express POU4F2+. By this approach, we found that a significantly higher percentage of BrdU+ RPCs exit the cell cycle and form RGCs in the Ccnd1-/- retina from E13.5 to E14.5 (Figure (Figure4J),4J As described above, the apical 'gap' of PCNA expression in the Ccnd1-/- retina is filled with OTX2+ cells (Additional file 5D–F). Since OTX2+ cells include both cone and rod precursors, we examined the P0 expression patterns of retinoid × receptor gamma (RXRγ) and nuclear receptor subfamily 2, group E, member 3 (NR2E3), which mark cone and rod precursors respectively [34-36]. Consistent with the increase in OTX2+ cells, the proportions of RXRγ+ cells (Figure 5A, D, G
The proportions of horizontal and amacrine cells are reduced in the Ccnd1-/- retina, despite increased cell cycle exit Since the decrease in the relative proportion of the RPC population correlates with increased neurogenesis in the embryonic Ccnd1-/- retina, it stands to reason that the proportions of other early-born cell types, such as horizontal and amacrine cells, would also be increased. We found, however, that these cell types are in fact underrepresented at E17.5 (data not shown) and P0 (Figure (Figure6).6
Ccnd1 deficiency has different effects on distinct precursor populations Although our analysis of apoptosis (Additional file 2 and data not shown) suggests that cell death is not contributing to the embryonic phenotype, we cannot entirely rule it out as a factor in causing the reduction in horizontal cells and SOX2+, ISL1+ amacrine cells as these cell types are normally in low abundance. Furthermore, as it is hard to discern NEFM+ horizontal cells during early neurogenesis and SOX2 expression is indicative of advanced stages of maturation, the reductions in these markers could also be due to delayed differentiation. This is unlikely, however, as cells expressing these markers continue to appear reduced at later ages (data not shown). Another possibility is that the Ccnd1 deficiency is causing an underproduction in the post-mitotic precursors from which these particular cell types arise. To address this, we examined retinas at earlier stages of development using markers expressed in newly generated precursors of horizontal, amacrine, and photoreceptor cells (Figure (Figure7).7
Whereas a few cells in the E12 wild-type dorsal retina express PTF1A, significantly fewer PTF1A+ cells are detected in the Ccnd1-/- retina (Figure 7A, D, G To gain insight into the potential relationships between these precursor populations, we directly compared the expression patterns of PTF1A, BHLHB5, and OTX2 at E12, E14.5 and P0 (Figure (Figure8).8
Ccnd2 cannot completely rescue the Ccnd1-/- retinal phenotype Genetic replacement of Ccnd1 by Ccnd2 in Ccnd1D2/D2 knock-in mice restores the histological appearance of the adult retina and electroretinographic response of photoreceptors [22]. In this model, the Ccnd2 cDNA sequence is inserted into the Ccnd1 locus and regulated by the Ccnd1 promoter and enhancer elements. We examined the P0 retina in these mice to determine if Ccnd2 is sufficient to correct the developmental changes due to Ccnd1 deficiency (Figure (Figure9).9
Genetic manipulation of downstream cell cycle regulators minimizes the impact of the Ccnd1 deficiency on embryonic retinal development Genetic and biochemical evidence suggests that the rate-limiting function of Ccnd1 in promoting cell cycle progression is to stimulate Ccne activity [23]. Based on this model, the altered cell production in the Ccnd1-/- RPC population could be due to limited Ccne activity. To address this, we analyzed the newborn retina in a mouse strain in which the human Ccne cDNA is inserted into the Ccnd1 locus. In this strain, referred to as Ccnd1hE/hE, human Ccne is expressed in place of Ccnd1. Similar to the Ccnd1D2/D2 mouse, the adult retina in this model appears histologically normal and electrophysiological properties are better than in the Ccnd1-/- retina [23]. Our initial analysis revealed that the Ccnd1hE/hE retina is thinner than its wild-type counterpart, which may be due to an increase in apoptosis, especially in the NBL (Figure 9K–N The sequestration of P27KIP1 by CCND1 protein is one mechanism by which CCND1 is predicted to enhance CCNE activity and promote cell cycle progression [11]. Consistent with this, genetic inactivation of p27Kip1 alleviates many of the phenotypes seen in the Ccnd1-/- mouse [46,47]. Furthermore, ectopic proliferation occurs in the p27Kip1-/- retina and its overexpression inhibits RPC proliferation [48,50]. To test whether the removal of p27Kip1 restores the balance of cell types in the absence of Ccnd1, we analyzed Ccnd1-/-, p27Kip1-/- double mutant retinas at P0 (Additional file 7). We found that the expression pattern of PCNA in the double mutant retina is more similar to the control retina (Ccnd1+/-) than to the Ccnd1-/- retina, which is indicated by the absence of an 'apical gap' in staining (Additional file 7A, G, S). The cellular distributions of POU4F2+ RGCs, NEFM+ horizontal cells as well as other cell populations expressing PTF1A, SOX2, and BHLHB5 in the double mutant also appear more similar to the control patterns than those in the Ccnd1-/- retina (Additional file 7B–F, H–L, T–X). For comparative purposes, the expression patterns for these markers in the p27Kip1-/- retina are shown in Additional file 7M–R. The sum of our observations from the Ccnd1hE/hE and Ccnd1-/-, p27Kip1-/- mice suggest that Ccnd1's influence on precursor cell output is dependent on its role in regulating Ccne and p27Kip1. Discussion We report here that Ccnd1 has important functions in regulating embryonic retinal histogenesis. In addition to hypocellularity due to changes in proliferation, the relative proportions of multiple post-mitotic precursor populations are altered in the Ccnd1-/- retina. RGC precursors are overrepresented, and horizontal cell and a subset of amacrine cell precursors are underrepresented in the Ccnd1-/- retina relative to wild type. Photoreceptor precursors, while underrepresented early on, are overrepresented later. Since overall cell number is lower in the mutant retina [21], our data suggest that the initial reduction in photoreceptor precursors and the apparent permanent reduction in horizontal and amacrine cell precursors reveals a true reduction in their numbers compared to wild type. While it is not known if the absolute number of RGCs and photoreceptors differs from wild type, our data show that their relative contributions to the cell composition of the Ccnd1-/- retina is greater than in wild type. The changes outlined above are likely to be the result of Ccnd1's roles in the cell cycle. Since cell cycle transit time is longer and the relative rate of cell cycle exit is enhanced in the absence of Ccnd1, it is possible that these changes in proliferation are linked. While longer cell cycle times are predictive of increased cell cycle exit in the brain [51,52], this does not appear to be the case in the zebrafish retina [53,54]. So whether the lengthening of the cell cycle directly causes enhanced cell cycle exit in the Ccnd1-/- retina is not clear. Regardless, we propose that Ccnd1 is required for establishing the proper balance of cell types produced during embryonic retinal development by mediating cell cycle exit, or in other words, the rate of precursor output from RPCs. Ccnd1 regulates the timing of cell cycle exit in a limited manner after the onset of neurogenesis Interestingly, not all Ccnd1-/- RPCs exit prematurely, and the extent of RPC depletion, while significant, is not severe. A reasonable percentage of Ccnd1-/- RPCs remain in the cell cycle even as neurogenesis progresses. This is not due to restricted expression as Ccnd1 is widely expressed in RPCs and throughout most of the cell cycle (this study) [15,18]. Rather, D-cyclins are not absolutely required for proliferation in embryonic RPCs since proliferation still occurs in mice deficient in Ccnd1, Ccnd2, and Ccnd3 [14]. We also found no evidence that Ccnd1-/- RPCs exit the cell cycle before the normal onset of neurogenesis even though Ccnd1 is abundantly expressed as early as E9.5. This is not because RPCs are inherently unable to initiate neurogenesis early since precocious neurons are produced in the paired box gene 6 (Pax6-/-) and hairy and enhancer of split 1 (Hes1-/-) retinas [55,57]. Furthermore, the spreading wave of neurogenesis is not altered in the Ccnd1-/- retina, even though wild-type RPCs increase their level of CCND1 expression just ahead of the neurogenic wave. These observations led us to propose a model stating that once neurogenesis begins, a limited number of RPCs become Ccnd1-dependent and their timing of cell cycle exit is determined by their level of CCND1 expression or activity (Figure 10A
Mechanism of Ccnd1-mediated cell cycle exit D-cyclins regulate the retinoblastoma pathway by binding to and activating CDK4/6 and by sequestering CDK2 inhibitors such as P27KIP1 [11]. Both mechanisms ultimately lead to inactivation of retinoblastoma proteins by CDK2/4/6-mediated phosphorylation, allowing cells to progress from G1 to S phase and undergo DNA replication. Although the importance of the retinoblastoma pathway in continuously cycling cells is not clear, it is critical in many cell lineages for differentiation [59-61]. In the mouse retina, genetic deletion of the retinoblastoma proteins (Rb1, Rbl1/p107, or Rbl2/p130) uncouples cell cycle exit and differentiation, resulting in ectopic proliferating cells that express markers of multiple precursor cell types in the retina [62,65]. Further evidence of this decoupling is seen in the postnatal p107 single copy mutant retina where mature horizontal cells proliferate extensively, all the while retaining their differentiated characteristics [66]. This suggests that retinoblastoma pathway activity regulates cell cycle exit of RPCs and controls the post-mitotic state for some period of time after cell cycle exit. Additional evidence to this effect comes from genetic studies of molecular regulators in this pathway: inactivation of cyclin-dependent kinase inhibitors such as p27Kip1, p57Kip2, and p19Ink4d cause ectopic proliferation [9,48,50,67]. Forced expression of Ccnd1, the large T-antigen from simian virus 40 or the human papillomavirus type 16 (HPV-16) E7 protein (negative regulators of retinoblastoma proteins) in post-mitotic photoreceptor precursors causes inappropriate cell cycle re-entry and subsequent cell death or tumorigenesis depending on the nature of the transgene construct [58,68-72]. A similar phenomenon is also observed for other retinal cell types [73,75]. Furthermore, Rb1 phosphorylation is greatly diminished in the Ccnd1-/- retina, probably due to reductions in CDK2 and CDK4 activities [23,46,47,76]. Since the retinoblastoma proteins are expressed in dynamic and temporal patterns in mouse RPCs [60,64,77], their expression levels in individual RPCs may determine the timing of Ccnd1-dependence (Figure 10A Our results indicate that Ccnd2 may not influence RPC cell cycle exit in the same manner as Ccnd1. Although the retina in the Ccnd1D2/D2 mouse is not as severely affected as in the Ccnd1-/- mouse, cell production is not restored to normal proportions. Limited Ccnd2 expression is not the likely reason for this [22]. Rather, molecular analyses indicate that CCND2 activity is not identical to CCND1 [22,46,47,78]. The newborn Ccnd1hE/hE retina also has a more normal cellular composition than the Ccnd1-/- retina and may surpass the extent of rescue in the Ccnd1D2/D2 retina. Interpretation of the phenotype is complicated by enhanced cell death, which is not observed in the newborn Ccnd1-/- or Ccnd1D2/D2 retinas. This is probably due to high hCcne expression as endogenous Ccne is normally expressed at low levels [18] (unpublished observations). While hCcne may rescue premature cell cycle exit due to the Ccnd1 deficiency, it could also activate apoptosis by causing an incompatible activation of proliferation and differentiation pathways in precursor cells. Nevertheless, instead of functionally replacing Ccnd1, ectopically expressed hCCNE bypasses the retinoblastoma proteins [23], by partnering with CDK2 to induce S-phase entry without sufficient RB1 phosphorylation [79]. A similar bypass mechanism appears to be operating in the Ccnd1-/-, p27Kip1-/- retina [46,47] and the more normal distribution of cell types in the newborn Ccnd1-/-, p27Kip1-/- retina at P0 supports the idea that p27Kip1 is downstream of Ccnd1 in regulating the production of precursor populations. The sum of these findings agrees with the model that Ccnd1-mediated regulation of the retinoblastoma pathway is an important mechanism for controlling the timing of cell cycle exit in embryonic RPCs. Ccnd1 influences the production of precursor cells allocated to multiple cell types In multipotential progenitor cell lineages, enhanced rates of cell cycle exit tend to cause reductions in late-born cell types that may or may not be accompanied by increases in the production of early-born cell types [55,57,80-83]. Interestingly, the changes in cell production that occur in the embryonic Ccnd1-/- retina diverge from this general rule. RGC production is enhanced whereas unexpectedly, production of other early-born cell types, namely horizontal cells, SOX2+, ISL1+ amacrine cells, and cones (initially), is reduced, and these types of alterations are indicative of changes in cell fate specification (Figure 10B One possibility is that Ccnd1 has an instructive role in retinal cell fate determination, similar to Ccne in the thoracic NB6-4 neuroblast lineage in Drosophila [84]. Ccnd1 may prevent a subset of early neurogenic RPCs from becoming RGCs by directing them toward horizontal, amacrine, or cone cell fates. Indeed, production of PTF1A+ precursors is reduced in the Ccnd1-/-retina, and Ptf1a inactivation results in a cell fate switch from horizontal and amacrine cells to RGCs [39-41]. Although OTx2+ (and RXRγ+) precursors are also underrepresented in the Ccnd1-/- retina at E12 and E14.5, it is unclear how Ccnd1 could instruct photoreceptor fate since inactivation of OTx2 in photoreceptor precursors causes conspicuous amacrine cell overproduction and apoptosis by P0 [45], two changes not observed in the Ccnd1-/- retina. Regardless, if Ccnd1 is instructive for cell fate, we predict that the mechanism involved could operate independently of its role in timing RPC cell cycle exit since altering precursor cell fates does not necessarily involve changes in proliferation. Another possibility is that Ccnd1 deficiency could produce cell fate changes that are linked to the altered timing of cell cycle exit (Figure 10B An unresolved issue, however, is that while this model accounts for enhanced RGC production early and photoreceptor production late, it fails to explain the persistent underproduction of other early-born cell types in the mutant. If RPCs are multipotential and premature cell cycle exit is a continuous and ongoing process in the Ccnd1-/- retina, then the RPCs that exit subsequently should compensate for the earlier exited RPCs and produce the precursors that are initially underproduced. While this is observed for the OTX2+, RXRγ+ precursors (cones), production of PTF1A+ precursors (horizontal cells and some amacrine cells) fails to 'catch up'. One possibility is that most RPCs lose their competence to produce PTF1A+ precursors (R* in Figure 10B The BHLHB5+ cell population is unique in that its proportion does not vary between the wild type in the Ccnd1-/- retina, at least up to P0. Given the idea that subsets of RPCs may utilize different proteins to control cell cycle exit [18], BHLHB5+ precursors may not require Ccnd1 to regulate the number of RPCs needed for their production. The fact that the proportion of BHLHB5+ precursors remains consistent may also be an indication that production of this cell population is dependent on non-cell autonomous feedback signaling [86-88]. As mentioned at the start of this section, a more rapid rate of RPC depletion due to enhanced neurogenesis should cause a reduction or absence in the last generated cell types. Interestingly, rods, bipolar cells, and Müller glia are present in the postnatal Ccnd1-/- retina as are PCNA+ cells [21] (unpublished observations), which indicates that RPCs persist until the last stages of normal histogenesis. This could occur if our model of Ccnd1-dependence in embryonic RPCs also holds for postnatal RPCs. If true, then the rate of RPC decline may not be steep enough to deplete the population prior to production of the last-born cell types, although again, we would expect a drop in their numbers. Our observation of an increased proportion of rod precursors at P0 suggests that they are being produced at the expense of bipolar cells and Müller glia, similar to what may be happening for RGC precursors and the other early-generated precursor populations. Assessing this is difficult, however, because of the extensive cell death in the postnatal Ccnd1-/- retina, when bipolar cells and Müller glia are being produced [21,89]. Alternatively, RPCs in the postnatal period may not require Ccnd1 to control timing of cell cycle exit, and one possible explanation is that Ccnd3 takes over, a scenario analogous to D-cyclin utilization in cerebellar granule precursors, which depend on Ccnd1 early and Ccnd2 late, to produce the correct number of granule cells [82,90]. Ccnd3 is normally expressed in Müller glia and possibly in RPCs at the end of histogenesis (that is, P5 and older). Importantly, CCND3 expression is upregulated by P0 in the Ccnd1-/- retina (unpublished observation) [47], which suggests a possible compensatory mechanism for maintaining postnatal RPCs. Does Ccnd1 regulate laminar positioning of retinal cells? Retinal cells occupy distinct locations in the retina and cells of the same cell type generally occupy the same laminar position. Unexpectedly, we found that the locations of cells belonging to several different classes are altered in the Ccnd1-/- retina. For example, RGCs are distributed on both sides of the IPL and horizontal cells are positioned closer than normal to the IPL. Why this occurs is not clear, but Ccnd1 can influence cell migration via the ROCK pathway [91,92]. Important to note, however, is that horizontal cells briefly reside in this position during their normal course of differentiation [93,94]. Whether Ccnd1 has a direct role in regulating precursor cell positioning/migration or if these changes are due to indirect effects of altered differentiation or because of compromised cell-cell interactions due to the changes in the proportions of retinal cell types awaits further analysis. Conclusion This study elucidates the roles of Ccnd1 in embryonic retinal development. We show that Ccnd1 is expressed globally in RPCs and contributes to two aspects of proliferation control – the rate of cell cycle progression and the timing of cell cycle exit. Ccnd1 is also required to ensure that precursor populations are produced in their appropriate proportions. We propose that Ccnd1 does this through its control of cell cycle exit and that the permanent reduction in the PTF1A+ precursor population in the Ccnd1-/- retina is the result of a temporal shift in RPC competence. More studies are needed to address whether Ccnd1 also has a direct role in regulating precursor fates and, if so, whether p27Kip1 or other cell cycle regulators that are downstream of Ccnd1 are involved. This work provides further evidence for the model that cell cycle regulators contribute to the neurogenic output of multipotential progenitor populations. Abbreviations BrdU: 5-bromo-2'-deoxy-uridine; DCL: differentiated cell layer; E: embryonic day; EdU: 5-ethynyl-2'-deoxy-uridine; IdU: 5-iodo-2'-deoxy-uridine; IPL: inner plexiform layer; NBL: neuroblast layer; P: postnatal day; RGC: retinal ganglion cell; RPC: retinal progenitor cell. Competing interests The authors declare that they have no competing interests. Authors' contributions EML and GD conceived the study and contributed to the experimental design, interpretation of data, and preparation of the figures and manuscript. GD contributed to the experimental design, collected and analyzed the data, and prepared the figures and manuscript. YC bred and genotyped the knock-in mouse lines, and prepared the eyes for analysis. EML and PS oversaw the work done in their respective laboratories. All authors read and approved the manuscript. Additional file 1 Expression domains of neural retina and retinal pigmented epithelium markers are not altered in the Ccnd1-/- eye prior to the onset of neurogenesis. Wild-type and Ccnd1-/- retinas at E9.5 and E11 were stained with antibodies against (A, B, I, J) PAX6, (C, D, K, L) SOX2, (E, F, M, N) VSX2 and (K, L, O, P) MITF. The asterisk in (D) indicates that this region of the neuroepithelium is folded over in the section. Abbreviations: NR, neural retina; OV, optic vesicle; PNR, presumptive neural retina; PRPE, presumptive retinal pigmented epithelium; RPE, retinal pigmented epithelium. Scale bar: 100 μm; (P) is representative for (A-P). Click here for file(865K, tiff) Additional file 2 Cell death is not altered in the Ccnd1-/- retina during embryonic development. Sections from (A-D) wild-type (wt) and (E-H) Ccnd1-/- retinas were stained with an antibody against activated-CASPASE 3, a marker of dying cells. No differences were observed in the pattern or number of immunoreactive cells at E12, E14.5, or E17.5. At P0, Ccnd1-/- retinas showed a slight increase in the number of activated CASP3+ cells. Bright dots in (D) are non-specific background staining. Scale bars: 100 μm; (G) is representative for (A, C, E, G); (H) for (B, D, F, H). Click here for file(1.4M, jpeg) Additional file 3 Phosphorylated histone H3 immunoreactivity. Expression patterns of pHH3 at (A, D) E12, (B, E) E14.5, and (C, F) P0 in wild-type (wt) (A-C) and Ccnd1-/- retinas (D-F) are shown. Scale bars: 100 μm; (D) is representative for (A, D); (F) for (B, C, E, F). Click here for file(626K, jpeg) Additional file 4 Co-expression patterns of retinal progenitor cell markers are maintained in the Ccnd1-/- retina. (A-D) Expression patterns of VSX2 and HES1 at E12 (A, B) and P0 (C, D) in wild-type (wt) retinas are shown. (E-H) Expression patterns of VSX2 and HES1 at E12 (E, F) and P0 (G, H) in Ccnd1-/- retinas are shown. (I-N) Co-expression patterns of PCNA and VSX2 at P0 in wild-type (I-K) and Ccnd1-/- retinas (L-N) are shown. (O-T) Co-expression patterns of PCNA and HES1 at P0 in wild-type (O-Q) and Ccnd1-/- retinas (R-T) are shown. Note that in all cases the co-expression relationships are maintained, indicating that the altered expression patterns in the Ccnd1-/- retina are due to the decrease in retinal progenitor cell numbers and not to direct regulation of the marker proteins. Abbreviations: NR, neural retina. Scale bars: 100 μm; (H) is representative for (A-H); (T) for (I-T). Click here for file(455K, jpeg) Additional file 5 Co-expression patterns of PCNA and OTX2 in Ccnd1-/-, Ccnd1D2/D2, and Ccnd1hE/hE retinas at P0. (A-R) Ccnd1-/- (D-F), Ccnd1D2/D2 (J-L) and Ccnd1hE/hE (P-R) retinas and their respective wild type controls ((A-C), (G-I), and (M-O), respectively) at P0 were double-labeled with antibodies against PCNA and OTX2 Merged images show that OTX2-expressing cells completely fill the PCNA- 'gap' in the Ccnd1-/- and Ccnd1D2/D2 retinas (F, L). Abbreviations: DCL, differentiated cell layer; NBL, neuroblast layer; PRL, photoreceptor cell layer; RPE, retinal pigmented epithelium. Scale bar: 100 μm; (R) is representative for all panels. Click here for file(585K, jpeg) Additional file 6 Expression patterns of POU4F2, PTF1A, SOX2, and BHLHB5 in Ccnd1D2/D2 and Ccnd1hE/hE retinas at P0. POU4F2 expression in (A, I) wild-type (wt) controls, (E) Ccnd1D2/D2 and (M) Ccnd1hE/hE retina at P0, is shown. PTF1A expression in (B, J) wild-type controls, (F) Ccnd1D2/D2 and (N) Ccnd1hE/hE retina at P0 is shown. SOX2 expression in (C, K) wild-type controls, (G) Ccnd1D2/D2 and (O) Ccnd1hE/hE retina at P0 is shown. BHLHB5 expression in (D, L) wild-type controls, (H) Ccnd1D2/D2 and (P) Ccnd1hE/hE retina at P0 is also shown. Abbreviations: NR, neural retina. Scale bar: 100 μm; (P) is representative for all panels. Click here for file(651K, tiff) Additional file 7 Expression patterns of PCNA, POU4F2, NEFM, PTF1A, SOX2, and BHLHB5 in wild type (Ccnd1+/-), Ccnd1-/- single null, p27Kip1-/- single null, and Ccnd1-/-, p27Kip1-/-double null retinas at P0. (A, G, M, S) PCNA expression in retinal progenitor cells, showing absence of a significant apical gap in the Ccnd1-/-, p27Kip1-/- double null (S) compared to Ccnd1-/- (G). The distributions of (B, H, N, T) POU4F2+ retinal ganglion cells, (C, I, O, U) NEFM+ horizontal cells in the outer neuroblast layer, (D, J, P, V) PTF1A+, (E, K, Q, W) SOX2+ and (F, L, R, X) BHLHB5+ precursors in the double null (bottom row) are more similar to wild type (top row) than to the Ccnd1-/-(second row). Expression patterns for each of the markers in the p27Kip1-/- retina (third row) are shown for comparison. Scale bar: 100 μm; (X) is representative for all panels. Click here for file(7.7M, tiff) Acknowledgements We thank Dr Sabine Fuhrmann for critical reading of the manuscript and members of the Levine and Fuhrmann laboratories for their insights and assistance. We also thank Drs Nadean Brown, Helena Edlund, Alejandro Sanchez-Alvarado, and Anand Swaroop for reagents and advice. The ISL1 and PAX6 monoclonal antibodies, developed by Drs TM Jessell and A Kawakami, respectively, were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA, USA. This work was supported by R01 grants EY013760 (EML), CA108950 (PS), and CA083688 (PS), by NEI vision core grant EY0014800, and unrestricted funding by Research to Prevent Blindness to the Moran Eye Center. EML is a Research to Prevent Blindness Sybil Harrington Scholar and PS is a Fellow of the Leukemia and Lymphoma Society. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||
J Neurosci. 1998 Nov 1; 18(21):8936-46.
[J Neurosci. 1998]Brain Res. 2008 Feb 4; 1192():5-16.
[Brain Res. 2008]J Comp Neurol. 2005 Aug 15; 489(1):120-34.
[J Comp Neurol. 2005]Prog Neurobiol. 1989; 32(3):207-34.
[Prog Neurobiol. 1989]Dev Dyn. 1996 Mar; 205(3):293-307.
[Dev Dyn. 1996]J Comp Neurol. 2004 Jun 21; 474(2):304-24.
[J Comp Neurol. 2004]Nat Rev Neurosci. 2001 May; 2(5):333-42.
[Nat Rev Neurosci. 2001]Brain Res. 2008 Feb 4; 1192():37-60.
[Brain Res. 2008]Cell Cycle. 2005 Mar; 4(3):388-91.
[Cell Cycle. 2005]Growth Factors. 2006 Mar; 24(1):13-9.
[Growth Factors. 2006]Genes Dev. 2002 Dec 15; 16(24):3277-89.
[Genes Dev. 2002]Cell. 2004 Aug 20; 118(4):477-91.
[Cell. 2004]PLoS One. 2008 Feb 13; 3(2):e1588.
[PLoS One. 2008]Nucleic Acids Res. 2005; 33(15):4914-21.
[Nucleic Acids Res. 2005]Cell. 1995 Aug 25; 82(4):621-30.
[Cell. 1995]Genes Dev. 1995 Oct 1; 9(19):2364-72.
[Genes Dev. 1995]Proc Natl Acad Sci U S A. 1998 Aug 18; 95(17):9938-43.
[Proc Natl Acad Sci U S A. 1998]Cell. 1995 Aug 25; 82(4):621-30.
[Cell. 1995]Mol Cell Biol. 2005 Feb; 25(3):1081-8.
[Mol Cell Biol. 2005]Cell. 1996 May 31; 85(5):733-44.
[Cell. 1996]Brain Res. 2008 Feb 4; 1192():99-113.
[Brain Res. 2008]Development. 2008 Feb; 135(4):729-41.
[Development. 2008]Dev Biol. 2007 Feb 1; 302(1):50-65.
[Dev Biol. 2007]Biotechniques. 2008 Jun; 44(7):927-9.
[Biotechniques. 2008]Cell. 1995 Aug 25; 82(4):621-30.
[Cell. 1995]Brain Res. 2007 Oct 24; 1176():11-7.
[Brain Res. 2007]Dev Biol. 2008 May 15; 317(2):560-75.
[Dev Biol. 2008]Proc Natl Acad Sci U S A. 1998 Aug 18; 95(17):9938-43.
[Proc Natl Acad Sci U S A. 1998]Eur J Neurosci. 2005 Feb; 21(3):803-7.
[Eur J Neurosci. 2005]Dev Biol. 1999 Jun 15; 210(2):469-80.
[Dev Biol. 1999]J Neurosci. 2008 Mar 26; 28(13):3392-403.
[J Neurosci. 2008]Invest Ophthalmol Vis Sci. 2001 May; 42(6):1312-8.
[Invest Ophthalmol Vis Sci. 2001]Genes Dev. 2006 May 1; 20(9):1187-202.
[Genes Dev. 2006]BMC Dev Biol. 2007 Oct 2; 7():110.
[BMC Dev Biol. 2007]Development. 2007 Mar; 134(6):1151-60.
[Development. 2007]Development. 2006 Dec; 133(24):4815-25.
[Development. 2006]Brain Res Mol Brain Res. 2000 May 31; 78(1-2):26-37.
[Brain Res Mol Brain Res. 2000]Nat Neurosci. 2003 Dec; 6(12):1255-63.
[Nat Neurosci. 2003]Mol Cell Biol. 2005 Feb; 25(3):1081-8.
[Mol Cell Biol. 2005]Cell. 1999 Jun 11; 97(6):767-77.
[Cell. 1999]Cell Cycle. 2005 Mar; 4(3):388-91.
[Cell Cycle. 2005]Proc Natl Acad Sci U S A. 2001 Jan 2; 98(1):194-9.
[Proc Natl Acad Sci U S A. 2001]Mol Cell Biol. 2001 Feb; 21(4):1319-28.
[Mol Cell Biol. 2001]Dev Biol. 2000 Mar 15; 219(2):299-314.
[Dev Biol. 2000]Mol Cell Neurosci. 2002 Mar; 19(3):359-74.
[Mol Cell Neurosci. 2002]Proc Natl Acad Sci U S A. 1998 Aug 18; 95(17):9938-43.
[Proc Natl Acad Sci U S A. 1998]J Neurosci. 2005 Jul 13; 25(28):6533-8.
[J Neurosci. 2005]J Cell Sci. 2003 Dec 15; 116(Pt 24):4947-55.
[J Cell Sci. 2003]J Neurosci. 2007 Sep 19; 27(38):10143-52.
[J Neurosci. 2007]BMC Dev Biol. 2007 Apr 5; 7():28.
[BMC Dev Biol. 2007]PLoS One. 2008 Feb 13; 3(2):e1588.
[PLoS One. 2008]Cell. 2004 Aug 20; 118(4):477-91.
[Cell. 2004]Dev Biol. 2005 Aug 15; 284(2):464-78.
[Dev Biol. 2005]Neuron. 1996 Apr; 16(4):723-34.
[Neuron. 1996]Oncogene. 2001 Oct 11; 20(46):6742-51.
[Oncogene. 2001]Cell Cycle. 2005 Mar; 4(3):388-91.
[Cell Cycle. 2005]Oncogene. 2006 Aug 28; 25(38):5268-76.
[Oncogene. 2006]PLoS Biol. 2007 Jul; 5(7):e179.
[PLoS Biol. 2007]Nat Rev Cancer. 2005 Feb; 5(2):91-101.
[Nat Rev Cancer. 2005]Cancer Cell. 2004 Jun; 5(6):539-51.
[Cancer Cell. 2004]Mol Cell Biol. 2005 Feb; 25(3):1081-8.
[Mol Cell Biol. 2005]Proc Natl Acad Sci U S A. 2001 Jan 2; 98(1):194-9.
[Proc Natl Acad Sci U S A. 2001]Mol Cell Biol. 2001 Feb; 21(4):1319-28.
[Mol Cell Biol. 2001]Cell Cycle. 2005 Feb; 4(2):330-8.
[Cell Cycle. 2005]PLoS One. 2008 Feb 13; 3(2):e1588.
[PLoS One. 2008]Dev Biol. 2005 Aug 15; 284(2):464-78.
[Dev Biol. 2005]Neuron. 1996 Apr; 16(4):723-34.
[Neuron. 1996]Science. 1995 Nov 10; 270(5238):983-5.
[Science. 1995]Development. 2002 May; 129(10):2435-46.
[Development. 2002]Nat Cell Biol. 2005 Jan; 7(1):56-62.
[Nat Cell Biol. 2005]BMC Dev Biol. 2007 Oct 2; 7():110.
[BMC Dev Biol. 2007]Development. 2007 Mar; 134(6):1151-60.
[Development. 2007]Nat Neurosci. 2003 Dec; 6(12):1255-63.
[Nat Neurosci. 2003]PLoS One. 2008 Feb 13; 3(2):e1588.
[PLoS One. 2008]Development. 1999 Feb; 126(3):555-66.
[Development. 1999]Neural Dev. 2007 Jun 8; 2():11.
[Neural Dev. 2007]Proc Natl Acad Sci U S A. 1998 Aug 18; 95(17):9938-43.
[Proc Natl Acad Sci U S A. 1998]J Comp Neurol. 1984 Nov 1; 229(3):362-73.
[J Comp Neurol. 1984]Development. 1999 May; 126(9):1927-35.
[Development. 1999]Development. 2006 Oct; 133(19):3929-37.
[Development. 2006]Mol Cell Biol. 2001 Feb; 21(4):1319-28.
[Mol Cell Biol. 2001]Mol Cell Biol. 2006 Jun; 26(11):4240-56.
[Mol Cell Biol. 2006]Cell Cycle. 2006 Nov 1; 5(21):2440-2.
[Cell Cycle. 2006]J Neurosci. 2007 Dec 19; 27(51):14099-107.
[J Neurosci. 2007]Development. 2004 Mar; 131(6):1343-51.
[Development. 2004]